RxDoctor Payments Data

Peter Wolk, MD

Cardiovascular Disease · Chico, CANPI 1679561286

Payments from drug & device makers

$55,617in general payments, 2019–2025

Across 991 payments — averaging $56.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$23K
  • Medtronic$13K
  • Abbott$5K
  • Amgen$2K
  • Abiomed$1K
  • Novartis$1K
  • plus $9K from 33 others

What the payments were for

  • Speaking & faculty fees$18,80034%
  • Travel & lodging$10,45019%
  • Food & beverage$26,08447%
  • Education$2831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,617 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$844,636
Medicare patients
5,304
Services billed
14,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban357$437,733
XareltoRivaroxaban193$230,829
EntrestoSacubitril/Valsartan169$225,532
Repatha SureclickEvolocumab119$125,985
JardianceEmpagliflozin48$61,435
FarxigaDapagliflozin Propanediol35$40,781
BrilintaTicagrelor47$40,747
MultaqDronedarone Hcl21$39,869
NexlizetBempedoic Acid/Ezetimibe33$19,943
EdarbyclorAzilsartan Med/Chlorthalidone37$19,686
Ezetimibe366$12,577
VascepaIcosapent Ethyl16$11,924
Atorvastatin Calcium989$9,953
Metoprolol Succinate536$8,077
Midodrine Hcl43$7,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$947$437,733357 claims
Johnson & JohnsonXarelto$23,357$230,829193 claims
NovartisEntresto$1,465$225,532169 claims
AstraZenecaFarxiga, Brilinta$1,093$81,52882 claims
Boehringer IngelheimJardiance$348$61,43548 claims
Sanofi-aventis U.S. LLCMultaq$309$39,86921 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$35$26,87459 claims
Esperion Therapeutics, Inc.Nexlizet$547$19,94333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →